Valganciclovir prophylaxis for cytomegalovirus infection in thoracic transplant patients: Retrospective study of efficacy, safety, and drug exposure

Transplant Infectious Disease

Volumn 12, Issue 3, 2010, Pages 213-219

  Lefeuvre, S ^a,b   Chevalier, P ^a   Charpentier, C ^a,b   Zekkour, R ^a   Havard, L ^a   Benammar, M ^a   Amrein, C ^a   Boussaud, V ^a   Lillo Le Louet A ^a   Guillemain, R ^a   Billaud, E M ^a,b  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Cytomegalovirus; Monitoring; Prophylaxis; Thoracic transplantation; Valganciclovir

Indexed keywords

BASILIXIMAB; CORTICOSTEROID; CYCLOSPORIN A; GANCICLOVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR; ANTIVIRUS AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GRAFT RECIPIENT; HEART LUNG TRANSPLANTATION; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; KIDNEY FUNCTION; LUNG FIBROSIS; LUNG TRANSPLANTATION; MALE; NEUTROPENIA; PRIORITY JOURNAL; SEROCONVERSION; THROMBOCYTOPENIA; AGED; ANALOGS AND DERIVATIVES; CHEMOPROPHYLAXIS; CYSTIC FIBROSIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG EFFECTS; INCIDENCE; ISOLATION AND PURIFICATION; MIDDLE AGED; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VIROLOGY; YOUNG ADULT;

ADULT; AGED; ANTIVIRAL AGENTS; CHEMOPREVENTION; CYSTIC FIBROSIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG MONITORING; FEMALE; GANCICLOVIR; HEART TRANSPLANTATION; HUMANS; INCIDENCE; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77953186844     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2010.00491.x     Document Type: Article

References (33)

1. Scott JC, Partovi N, Ensom MHH. Ganciclovir in solid organ transplant recipient. Ther Drug Monit 2004 26 (1) : 68 77.
2. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998 338 (24) : 1741 1751.
3. Marty FM, Rubin RH. The prevention of infection post-transplant: the role of prophylaxis, preemptive and empiric therapy. Transpl Int 2006 19 (1) : 2 11.
4. Kliem V, Fricke L, Wollbrink T, Burg M, Radermacher J, Rohde F. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant 2008 8 (5) : 975 983.
5. Wiltshire H, Hirankarn S, Farrell C, et al. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients. Clin Pharmacokinet 2005 44 (5) : 495 507.
6. Wiltshire H, Paya CV, Pescovitz MD, et al. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipient. Transplantation 2005 79 (11) : 1477 1483.
7. Asberg A, Humar A, Rollag H, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2007 7 (9) : 2106 2113.
8. Chamberlain CE, Penzak SR, Alfaro RM, et al. Pharmacokinetics of low and maintenance dose valganciclovir in kidney transplant recipients. Am J Transplant 2008 8 (6) : 1297 1302.
9. Ciancio G, Burke GW, Mattiazzi A, et al. Cytomegalovirus prophylaxis with valganciclovir in kidney, pancreas-kidney, and pancreas transplantation. Clin Transplant 2004 18 (4) : 402 406.
10. Paya C, Humar A, Dominguez E, et al, Valganciclovir Solid Organ Transplant Study Group. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004 4 (4) : 611 620.
11. Preiksaitis JK, Brennen DC, Fishman J, Allen U. Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 2005 5 (2) : 218 227.
12. Cytomegalovirus. Am J Transplant 2004 4 (Suppl 10) : 51 58.
13. Torres-Madriz G, Boucher HW. Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients. Clin Infect Dis 2008 47 (5) : 702 711.
14. Remund KF, Best M, Egan JJ. Infections relevant to lung transplantation. Proc Am Thorac Soc 2009 6 (1) : 94 100.
15. Jardine AG, Lebranchu Y, Vincenti F, et al. The impact study: prophylaxis with valganciclovir for up to 200 days post-transplant in high risk kidney recipients significantly reduces the incidence of CMV disease compared to 100 days use followed by placebo. Abstract O-337, 14th European Society for Organ Transplantation congress, September 30 to October 2, 2009, Paris, France.
16. Kijpittayarit-Arthurs S, Eid AJ, Kremers WK, et al. Clinical features and outcomes of delayed-onset primary cytomegalovirus disease in cardiac transplant recipients. J Heart Lung Transplant 2007 26 (10) : 1019 1024.
17. Gupta S, Mitchell JD, Markham DW, et al. High incidence of cytomegalovirus disease in D+/R- heart transplant recipients shortly after completion of 3 months of valganciclovir prophylaxis. J Heart Lung Transplant 2008 27 (5) : 536 539.
18. Humar A, Kumar D, Preiksaitis J, et al. A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients. Am J Transplant 2005 5 (6) : 1462 1468.
19. Schröeder R, Michelon T, Wurdig J, et al. The incidence of cytomegalovirus infection in lung transplant recipient under universal prophylaxis with intravenous ganciclovir. Braz J Infect Dis 2007 11 (2) : 212 214.
20. Husain S, Pietrangeli CE, Zeevi A. Delayed onset CMV disease in solid organ transplant recipients. Transpl Immunol 2009 21 (1) : 1 9.
21. Fisher RA. Cytomegalovirus infection and disease in the new era of immunosuppression following solid organ transplantation. Transpl Infect Dis 2009 11 (3) : 195 202.
22. Valentine VG, Bonvillain RW, Gupta MR, et al. Infections in lung allograft recipients: ganciclovir era. J Heart Lung Transplant 2008 27 (5) : 528 535.
23. Brum S, Nolasco F, Sousa J, et al. Leukopenia in kidney transplant patients with the association of valganciclovir and mycophenolate mofetil. Transplant Proc 2008 40 (3) : 752 754.
24. Humar A, Michaels M. American Society of Transplantation. Recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006 6 (2) : 262 274.
25. Campanero MA, Sadaba B, García-Quetglas E, Azanza JR. Development and validation of a sensitive method for determination of ganciclovir in human plasma samples by reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1998 706 (2) : 311 317.
26. Plotkin SA, Drew WL, Felsenstein D, Hirsch MS. Sensitivity of clinical isolates of human cytomegalovirus to 9-(1,3-dihydroxy-2-propoxymethyl)guanine. J Infect Dis 1985 152 (4) : 833 834.
27. Bienvenu B, Thervet E, Bedrossian J, et al. Emergence of cytomegalovirus resistance to ganciclovir after oral maintenance treatment in a renal transplant recipient. Transplant Proc 2000 32 (2) : 407. (Pubitemid 30133302)
28. Eid AJ, Arthurs SK, Deziel PJ, Wilhelm MP, Razonable RR. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes. Clin Transplant 2008 22 (2) : 162 170.
29. Chmiel C, Speich R, Hofer M, et al. Ganciclovir/valganciclovir prophylaxis decreases cytomegalovirus-related events and bronchiolitis obliterans syndrome after lung transplantation. Clin Infect Dis 2008 46 (6) : 831 839.
30. Valentine VG, Weill D, Gupta M, et al. Ganciclovir for cytomegalovirus: a call for indefinite prophylaxis in lung transplantation. J Heart Lung Transplant 2008 27 (8) : 875 881.
31. Zamora MR, Nicolls MR, Hodges TN, et al. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Am J Transplant 2004 4 (10) : 1635 1642.
32. Snell GI, Kotsimbos TC, Levvey BJ, et al. Pharmacokinetic assessment of oral ganciclovir in lung transplant recipients with cystic fibrosis. Antimicrob Chemother 2000 45 (4) : 511 516.
33. Perrottet N, Csajka C, Pascual M, et al. Population pharmacokinetics of ganciclovir in solid organ transplant recipients receiving oral valganciclovir. Antimicrob Agents Chemother 2009 53 (7) : 3017 3023.